Ocular immune privilege: therapeutic opportunities from an experiment of nature.
about
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trialDICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrateHigh-risk corneal allografts: A therapeutic challengeInvolvement of B cells in non-infectious uveitisOcular Immune Privilege and TransplantationThe Role of the IL-20 Subfamily in GlaucomaImmunopathogenic Background of Pars PlanitisMacrophages and Uveitis in Experimental Animal ModelsBacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infectionMechanisms of age-related macular degenerationImmunology of AAV-Mediated Gene Transfer in the EyePathogenesis of herpes stromal keratitis--a focus on corneal neovascularizationThe spleen in local and systemic regulation of immunityOcular surgical models for immune and angiogenic responses.Environmental microbes and uveitis: is microbial exposure always bad?The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vesselThe macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral toleranceEndogenous modulators of inflammatory cell recruitmentCell death, clearance and immunity in the skeletal muscleThe aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitisPersistent RNA virus infections: do PAMPS drive chronic disease?Natural Killer T Cells Contribute to Neutrophil Recruitment and Ocular Tissue Damage in a Model of Intraocular Tumor RejectionGlial grafting for demyelinating disease.Corneal graft rejection occurs despite Fas ligand expression and apoptosis of infiltrating cells.LruA and LruB, novel lipoproteins of pathogenic Leptospira interrogans associated with equine recurrent uveitisIntraocular route of AAV2 vector administration defines humoral immune response and therapeutic potentialRetinal laser burn disrupts immune privilege in the eye.Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury.Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.Anaphylatoxins Activate Ca2+, Akt/PI3-Kinase, and FOXO1/FoxP3 in the Retinal Pigment EpitheliumSafety evaluation of poly(lactic-co-glycolic acid)/poly(lactic-acid) microspheres through intravitreal injection in rabbits.Retinal Pigment Epithelial Cells are a Potential Reservoir for Ebola Virus in the Human Eye.A lesson in tolerance--maternal instruction to fetal cells.Diagnosis of systemic metastatic retinal lymphoma.Resolution, the grail for healthy ocular inflammation.Ocular immune privilege.NK cell depletion delays corneal allograft rejection in baby rats.Single compartment drug delivery.
P2860
Q24608049-2BCBD415-EE0D-4529-B656-960A33D91825Q24621930-E15E6942-3DA8-4E61-ACBB-494C12CFBFBEQ24634560-926F0D0C-D0CB-46CC-B41A-E6BFC970DA82Q24670380-6EC0F84E-481B-4486-AA2D-67DC58EAB4F8Q26751483-EA8F8EA9-080E-4C50-ACD2-3794F1DB80C4Q26766611-FDD0B462-69E8-4B98-ADFF-C802CCAFF2F1Q26767508-E151B941-C1F5-4F00-AEEB-4AACB5548AEBQ26768258-DBFFF22A-6521-4329-920B-446C61936A9DQ26781909-B1584EB8-371A-4ECB-AB1D-285D46012F06Q26828497-B6D2F546-B57F-4911-AAD0-F5BA5C91BE3BQ26998053-4CD4C03D-CBEA-4AE9-9E79-ECFEABE9CDDBQ27000182-822C623A-AF28-4326-8843-E5AB3D5C50B0Q27023474-568BF0E0-90C1-485C-A5BE-4035DFCDD423Q27023951-7495CD2C-D621-45A2-AE17-06C15B9C2A2BQ27025001-9611F137-67E6-4E61-83F5-A7578AEE9BA8Q27348742-262E47B9-576D-45A1-8738-1E06E20832A4Q28086831-C3AC37FF-501D-46F5-846F-00151CC855D9Q28244709-FB09EDD7-CCB2-40BC-AB49-361DAEEC9419Q28249483-CF00E911-8B27-429B-875B-C4774E825864Q28274305-B74C05E1-92C2-4B89-BACF-214EE2ACB6A9Q28386837-46C45792-8BC6-49D5-BCE8-DDD50E828BD6Q28578431-97B03C10-809B-4A02-8B7E-323538CA40EFQ28804036-9F7FE8B7-0F36-4372-9A17-861C91DF81E6Q30375264-10A3C93C-4AC6-4DF6-8E15-7F6913E257BAQ30500898-062CDC5E-3725-4139-9621-AE94813627BBQ33214095-4A971434-7AD6-43AB-9EC9-C99AA268BB44Q33225646-322D93E2-65CE-45C1-B17C-99F4B5D6A333Q33374015-2DC3318B-5671-4135-9674-75CBF63DE85AQ33400237-498AEDBE-2772-4AEA-AB42-104AA994A38CQ33556241-C56153BE-21C4-4D82-97AC-C9DB30593904Q33739804-B2DE7F7D-EE2F-4FCD-B5B9-45CEFB591301Q33802700-C235F95C-E6A8-43B9-A9E1-96F025F229AEQ33830339-FCBFCF00-1714-4B29-AAC6-7635B1B3F93BQ33909208-9054BDF6-A090-4923-8761-82E6A4BB7E10Q33915257-026825AF-3D9F-45CD-ADA0-FB53849E812DQ33940200-3D6E5B47-5FF1-49FE-AD1F-AF98438288A7Q34126362-4D82DF7A-088E-4B30-B79D-3FB57F389610Q34167552-AF9822AF-AD35-4D2C-96F2-3F4B1CE85129Q34208139-A387AADE-33B2-47A2-9D5F-C5B430910EB4Q34263907-100EC843-A4A5-4BC2-8C8B-0E5024995A02
P2860
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@ast
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@en
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@nl
type
label
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@ast
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@en
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@nl
prefLabel
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@ast
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@en
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@nl
P356
P1476
Ocular immune privilege: therapeutic opportunities from an experiment of nature.
@en
P2093
J Wayne Streilein
P304
P356
10.1038/NRI1224
P577
2003-11-01T00:00:00Z